These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 8814356)

  • 21. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities.
    Stéphan F; Etienne MC; Wallays C; Milano G; Clergue F
    Am J Med; 1995 Dec; 99(6):685-8. PubMed ID: 7503095
    [No Abstract]   [Full Text] [Related]  

  • 22. Porcine recombinant dihydropyrimidine dehydrogenase: comparison of the spectroscopic and catalytic properties of the wild-type and C671A mutant enzymes.
    Rosenbaum K; Jahnke K; Curti B; Hagen WR; Schnackerz KD; Vanoni MA
    Biochemistry; 1998 Dec; 37(50):17598-609. PubMed ID: 9860876
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Purification and characterization of dihydropyrimidine dehydrogenase from pig liver.
    Podschun B; Wahler G; Schnackerz KD
    Eur J Biochem; 1989 Oct; 185(1):219-24. PubMed ID: 2806259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dihydropyrimidine dehydrogenase activity: prognostic partner of 5-fluorouracil?
    Allegra CJ
    Clin Cancer Res; 1999 Aug; 5(8):1947-9. PubMed ID: 10473070
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
    van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
    Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination of the chemotherapeutic agent 5-fluorouracil with an inhibitor of its catabolism results in increased micronucleus induction.
    Stopper H; Kühnel A; Podschun B
    Biochem Biophys Res Commun; 1994 Sep; 203(2):1124-30. PubMed ID: 8093030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 5-fluorouracil sensitivity and dihydropyrimidine dehydrogenase activity in advanced gastric cancer.
    Inada T; Ogata Y; Kubota T; Tomikawa M; Yamamoto S; Andoh J; Ozawa I; Hishinuma S; Shimizu H; Kotake K
    Anticancer Res; 2000; 20(4):2457-62. PubMed ID: 10953310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of gastric cancer with decreased dihydropyrimidine dehydrogenase activity].
    Kobayashi K; Sumi S; Kidouchi K; Mizuno I; Mohri N; Fukui T; Akamo Y; Takeyama H; Manabe T
    Gan To Kagaku Ryoho; 1998 Jul; 25(8):1217-9. PubMed ID: 9679586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of dietary protein depletion on hepatic 5-fluorouracil metabolism.
    Davis LE; Lenkinski RE; Shinkwin MA; Kressel HY; Daly JM
    Cancer; 1993 Dec; 72(12):3715-22. PubMed ID: 8252488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil.
    Harvey VJ; Slevin ML; Dilloway MR; Clark PI; Johnston A; Lant AF
    Br J Clin Pharmacol; 1984 Sep; 18(3):421-30. PubMed ID: 6487480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.
    Mattison LK; Soong R; Diasio RB
    Pharmacogenomics; 2002 Jul; 3(4):485-92. PubMed ID: 12164772
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dihydropyrimidine dehydrogenase (DPD) and clinical pharmacology of 5-fluorouracil (review).
    Milano G; Etienne MC
    Anticancer Res; 1994; 14(6A):2295-7. PubMed ID: 7825962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy.
    Lu Z; Zhang R; Diasio RB
    Cancer Res; 1993 Nov; 53(22):5433-8. PubMed ID: 8221682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 5-Ethynyluracil (776C85): inactivation of dihydropyrimidine dehydrogenase in vivo.
    Spector T; Harrington JA; Porter DJ
    Biochem Pharmacol; 1993 Dec; 46(12):2243-8. PubMed ID: 8274158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Assay method for uracil, dihydrouracil, 5-fluorouracil and 5-fluoro-5, 6-dihydrouracil by high-performance liquid chromatography].
    Nakamura A; Kikuchi K; Ohishi T; Masuike T
    Gan To Kagaku Ryoho; 2004 Mar; 31(3):381-6. PubMed ID: 15045945
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.
    Okuda H; Ogura K; Kato A; Takubo H; Watabe T
    J Pharmacol Exp Ther; 1998 Nov; 287(2):791-9. PubMed ID: 9808711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy.
    Diasio RB; Lu Z
    J Clin Oncol; 1994 Nov; 12(11):2239-42. PubMed ID: 7964937
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency.
    van Kuilenburg AB; De Abreu RA; van Gennip AH
    Ann Clin Biochem; 2003 Jan; 40(Pt 1):41-5. PubMed ID: 12542909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Expression of thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase, E2F-1, Bak, Bcl-X, and Bcl-2, and clinical outcomes for gastric cancer patients treated with bolus 5-fluorouracil.
    Tahara M; Ochiai A; Fujimoto J; Boku N; Yasui W; Ohtsu A; Tahara E; Yoshida S
    Oncol Rep; 2004 Jan; 11(1):9-15. PubMed ID: 14654896
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency.
    Houyau P; Gay C; Chatelut E; Canal P; Roché H; Milano G
    J Natl Cancer Inst; 1993 Oct; 85(19):1602-3. PubMed ID: 8411234
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.